{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:12:03Z","timestamp":1768788723354,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ahj.2017.02.034","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T06:15:49Z","timestamp":1489472149000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF"],"prefix":"10.1016","volume":"188","author":[{"given":"Ulrik M.","family":"Mogensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-7397","authenticated-orcid":false,"given":"S\u00f8ren L.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Lefkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel R.","family":"Rizkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor C.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-2154","authenticated-orcid":false,"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-4027","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ahj.2017.02.034_bb0005","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2017.02.034_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2017.02.034_bb0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"issue":"8829","key":"10.1016\/j.ahj.2017.02.034_bb0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","article-title":"Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions","volume":"340","author":"Yusuf","year":"1992","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ahj.2017.02.034_bb0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ahj.2017.02.034_bb0030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"issue":"8875","key":"10.1016\/j.ahj.2017.02.034_bb0035","first-page":"821","volume":"342","year":"1993","journal-title":"Lancet"},{"issue":"9215","key":"10.1016\/j.ahj.2017.02.034_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ahj.2017.02.034_bb0045","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.1016\/j.ahj.2017.02.034_bb0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ahj.2017.02.034_bb0055","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/01.CIR.94.12.3103","article-title":"C-type natriuretic peptide in human coronary atherosclerotic lesions","volume":"94","author":"Naruko","year":"1996","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ahj.2017.02.034_bb0060","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.CIR.0000141802.29945.34","article-title":"Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia\/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide","volume":"110","author":"Hobbs","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2017.02.034_bb0065","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.ahj.2017.02.034_bb0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2017.02.034_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2017.02.034_bb0080","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0735-1097(96)00241-0","article-title":"C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems","volume":"28","author":"Wright","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.02.034_bb0085","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1006\/bbrc.1994.2731","article-title":"Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells","volume":"205","author":"Wei","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ahj.2017.02.034_bb0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/01.RES.81.4.585","article-title":"Effect of Natriuretic Peptide Family on the Oxidized LDL Induced Migration of Human Coronary Artery Smooth Muscle Cells","volume":"81","author":"Kohno","year":"1997","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ahj.2017.02.034_bb0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/002215540205000606","article-title":"Natriuretic peptide system gene expression in human coronary arteries","volume":"50","author":"Casco","year":"2002","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.ahj.2017.02.034_bb0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.atherosclerosis.2005.01.023","article-title":"C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention","volume":"181","author":"Naruko","year":"2005","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ahj.2017.02.034_bb0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.vph.2005.07.007","article-title":"NEP inhibitors enhance C-type natriuretic peptide-induced relaxation in porcine isolated coronary artery","volume":"43","author":"Marton","year":"2005","journal-title":"Vasc Pharmacol"},{"issue":"9851","key":"10.1016\/j.ahj.2017.02.034_bb0110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ahj.2017.02.034_bb0115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.110.940619","article-title":"Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"122","author":"Pouleur","year":"2010","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ahj.2017.02.034_bb0120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.amjmed.2005.02.010","article-title":"Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction","volume":"118","author":"Orn","year":"2005","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.ahj.2017.02.034_bb0125","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ahj.2017.02.034_bb0130","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","volume":"97","year":"1998","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317300893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317300893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:57:52Z","timestamp":1757570272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317300893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":26,"alternative-id":["S0002870317300893"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.02.034","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}